Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Maria Palmisano"'
Autor:
Rajula Gaur, Kofi A. Mensah, Jason Stricker, Mary Adams, Anastasia Parton, Dorota Cedzik, Jamie Connarn, Michael Thomas, Gerald Horan, Peter Schafer, Stuart Mair, Maria Palmisano, Francisco Ramírez-Valle
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-15 (2022)
Abstract Background Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is activated downstream of p38 MAPK and regulates stability of mRNAs encoding inflammatory cytokines. CC-99677 is a novel, irreversible, covalent MK2 inhibit
Externí odkaz:
https://doaj.org/article/bbdb650c3cdc4da7b9496d707ec64951
Autor:
Wei Gao, Hongxiang Hu, Lipeng Dai, Miao He, Hebao Yuan, Huixia Zhang, Jinhui Liao, Bo Wen, Yan Li, Maria Palmisano, Mohamed Dit Mady Traore, Simon Zhou, Duxin Sun
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 12, Iss 5, Pp 2462-2478 (2022)
Drug optimization, which improves drug potency/specificity by structure‒activity relationship (SAR) and drug-like properties, is rigorously performed to select drug candidates for clinical trials. However, the current drug optimization may overlook
Externí odkaz:
https://doaj.org/article/8f3478b4480b4cadbce522dd147c6570
Autor:
Ki Young Huh, Yewon Choi, Jim Nissel, Maria Palmisano, Xiaomin Wang, Liangang Liu, Francisco Ramirez‐Valle, Howard Lee
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1505-1511 (2021)
Abstract We performed a two‐part study to evaluate the pharmacokinetics, safety, and tolerability of oral apremilast, a phosphodiesterase 4 inhibitor indicated for the treatment of psoriasis, in healthy Korean adult men. In part 1, there were 12 su
Externí odkaz:
https://doaj.org/article/d3a249cc33ad4d829affa9ac366fadcf
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 2, Pp 119-126 (2021)
Ozanimod, approved by regulatory agencies in multiple countries for the treatment of adults with relapsing multiple sclerosis, is a sphingosine 1‐phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P receptor subtype
Externí odkaz:
https://doaj.org/article/26c31f775dcf4cb09154d184739c69a1
Autor:
Nianhang Chen, Nastya Kassir, Abderrahmane Laadem, Stephen E. Maxwell, Priya Sriraman, Ana Carolina Giuseppi, Steve Ritland, Peter G. Linde, Balasubrahmanyam Budda, Joseph G. Reynolds, Simon Zhou, Maria Palmisano
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 7, Pp 395-404 (2020)
Luspatercept is a recombinant fusion protein that enhances late‐stage erythroid maturation. This report describes the population pharmacokinetics and exposure–response relationship of luspatercept in 260 patients with anemia due to myelodysplasti
Externí odkaz:
https://doaj.org/article/b71c1d3971b14218bd2a4fcb5ebcb47a
Publikováno v:
Oncology and Therapy, Vol 8, Iss 1, Pp 91-102 (2019)
Abstract Introduction The purpose of this study was to evaluate the absolute bioavailability (BA) of AG-221 following a single oral dose of 100 mg AG-221 and an intravenous (IV) dose of ~ 100 μg AG-221 containing approximately 300 nCi of [14C]-AG-22
Externí odkaz:
https://doaj.org/article/d50ee59b08634cfea1ec1d57983793cf
Autor:
Emanuela Resta, Eustachio Cuscianna, Paola Pierucci, Carlo Custodero, Vincenzo Solfrizzi, Carlo Sabbà, Chiara Maria Palmisano, Federica Barratta, Maria Luisa De Candia, Maria Grazia Tummolo, Elena Capozza, Sonia Lomuscio, Lucrezia De Michele, Silvio Tafuri, Onofrio Resta, Gennaro Mariano Lenato
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
BackgroundExertional dyspnoea in post-COVID syndrome is a debilitating manifestation, requiring appropriate comprehensive management. However, limited-resources healthcare systems might be unable to expand their healthcare-providing capacity and are
Externí odkaz:
https://doaj.org/article/6b98a95bde9e477aab27554f80041d27
Autor:
Giuseppe Losurdo, Margherita De Bellis, Raffaella Rima, Chiara Maria Palmisano, Paola Dell’Aquila, Andrea Iannone, Enzo Ierardi, Alfredo Di Leo, Mariabeatrice Principi
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 24, p 7714 (2023)
The diagnosis of Crohn’s Disease (CD) is based on a combination of clinical symptoms, laboratory tests, endoscopy, and imaging data. In Small Intestine Contrast Ultrasonography (SICUS), the ingestion of a macrogol solution as an oral contrast mediu
Externí odkaz:
https://doaj.org/article/18d89b67a15e4db08105bb48a2cab53d
Autor:
Ying, Ye, Allison, Gaudy, Michael, Thomas, Josephine, Reyes, Barbara, Burkhardt, Gerald, Horan, Liangang, Liu, Jian, Chen, Atalanta, Ghosh, Leonidas N, Carayannopoulos, Daniel A, Tatosian, Maria, Palmisano
Publikováno v:
Clinical Pharmacology in Drug Development. 11:1394-1404
CC-90001 selectively inhibits c-Jun N-terminal kinase (JNK), a stress-activated protein implicated in fibrosis. In 3 phase 1 trials evaluating CC-90001 pharmacokinetics, pharmacodynamics, and safety, healthy adults (N = 184) received oral CC-90001 in
Autor:
Michael Thomas, Maria Palmisano, Mark Thomas, Sekhar Surapaneni, Yongjun Xue, Mary Liu, Simon Zhou, Rebecca N. Wood-Horrall, Gopal Krishna, Liangang Liu, Leonidas N Carayannopoulos, Ken Ogasawara
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:941-952
Fedratinib, an oral, selective Janus kinase 2 inhibitor, has been shown to inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic cation transporter (OCT) 2, and mul